Overview

Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)

Status:
Completed
Trial end date:
2012-10-30
Target enrollment:
Participant gender:
Summary
To investigate objective tumor response of AG-013736 for metastatic Renal Cell Cancer (mRCC)
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Axitinib